Systemic Treatment in Soft Tissue Sarcomas: Are We Making a Difference?

Soft tissue sarcomas [STSs] are rare tumors of mesodermal origin that arise in diverse tissues such as muscles, fat, and nerves. There are over 100 subtypes of STS, each with distinct clinical behaviors and responses to treatment. Recent advances in treatment have moved towards histology-specific approaches, emphasizing the integration of pathological, immunohistochemical, and molecular features to guide treatment.

Recent Developments in the Management of Renal Cell Cancer.

The management of renal cell carcinoma (RCC) has seen significant advancements in recent years with the introduction of novel therapeutic agents and combination regimens. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape, particularly for advanced and metastatic RCC, where ICI-based combinations have shown substantial improvements in survival outcomes. Dual immunotherapy combinations, such as nivolumab plus ipilimumab, and ICI-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations, including pembrolizumab with axitinib, nivolumab with cabozantinib, and pembrolizumab with lenvatinib, have demonstrated overall survival (OS) benefits in first-line treatment, redefining the standard of care for advanced RCC.

Natural History of subcentimeter pulmonary nodules in clinical stage I seminoma patients.

Introduction And Objective: Subcentimeter pulmonary nodules (SPN) found in clinical stage I (CS I) seminoma may be early pulmonary metastases or incidental, benign entities that may lead to patient anxiety and overtreatment. This study aims to demonstrate the incidence and natural history of SPN in CS I seminoma patients.

Methods: A retrospective study reviewing the medical records of CS I seminoma patients treated at UC San Diego Health between 2003 and 2023.

Specificity of a polygenic score for aggressive prostate cancer.

To address the concern that polygenic hazard scores for prostate cancer (PCa) might not distinguish between indolent and aggressive disease, we performed analyses using a 601-variant polygenic score (PHS601). We hypothesized that among men who eventually developed PCa, those with higher PHS were more likely to develop aggressive disease. We analyzed genetic and phenotypic data from a diverse, national cohort of men diagnosed with PCa (Million Veteran Program, n = 69,901, 6413 metastatic).

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening.

Importance: Continuing prostate-specific antigen (PSA) screening after age 70 years might benefit men at high risk of prostate cancer-specific mortality (PCSM) or metastatic prostate cancer (mPCa), but the relative value of clinical factors (race and ethnicity, competing mortality, and PSA history) in identifying men at higher vs lower risk is unknown.

Objective: To examine the value of PSA levels, race and ethnicity, and competing mortality in risk stratification for PCSM and mPCa in men after age 70 years.

Design, Setting, And Participants: In this cohort study, clinical data of all men receiving health care through the Veterans Health Administration who turned age 70 years between 2008 and 2020 and had a normal screening PSA value between age 65 and 69 years (<4 ng/mL [baseline PSA]) and no prior history of prostate cancer or biopsy were examined.